Novavax

Novavax, Inc. focuses on the discovery, development and commercialization of vaccines to prevent infectious diseases. It provides vaccines for COVID-19, seasonal flu, respiratory syncytial virus, Ebola, and Middle East respiratory syndrome. The company was founded in 1987 and is headquartered in Gaithersburg, MD.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Novavax reports strong revenue growth, focuses on fall vaccine launch

Novavax aims to deliver a competitive vaccine for the fall season, optimize cash flow, and mitigate risks. The company's focus on cost reduction and strategic investments align with its goal of long-term growth.

Novavax reports positive Phase 2 results and revenue guidance

Novavax's Q1 2023 earnings call highlighted positive Phase 2 trial results, revenue guidance, and cost-saving initiatives.
The company's focus on vaccine development, workforce reductions, and strategic collaborations bode well for future growth.
Challenges include ongoing arbitration with Gavi and managing global restructuring impacts on R&D efforts.
Opportunities lie in revenue growth, market expansion with Nuvaxovid, and leveraging technology for a robust vaccine portfolio.

Novavax reports robust Q2 earnings, anticipates strong revenue growth

Novavax is on track to deliver an updated vaccine for the fall season and expects strong revenue growth in 2023. They have significantly reduced liabilities, signed key agreements, and are investing in combination vaccines. Despite challenges ahead, the company remains committed to delivering successful performance.

Novavax reports strong Q3 results, eyes market share growth

Novavax is strategically positioned to drive long-term profitability with efficient cost structures.
The company's focus on innovation, cost reduction, and market expansion bodes well for future growth.
Despite challenges, Novavax's strong financial position and technology platform offer resilience and growth opportunities.

Novavax reduces expenses, targets growth with new vaccines in 2024

Novavax made significant strides in reducing expenses and liabilities in 2023, positioning for growth in 2024.
The company's focus on advancing its combination vaccine program and improving market share presents opportunities for expansion.
Challenges include improving U.S. market performance, addressing remaining liabilities, and securing regulatory authorizations.
Efforts to streamline operations, enhance customer engagement, and offer convenient products are key to Novavax's success in 2024.

Novavax reports strong Q1 earnings, secures $1.3B Sanofi deal

Novavax's Q1 2024 performance shows promising revenue growth, expense reduction, and strategic partnership with Sanofi driving cash flow improvements.
While facing challenges in managing the multibillion-dollar opportunity and regulatory pathways, Novavax is well-positioned to capitalize on revenue opportunities.
The company's focus on optimizing existing agreements, expanding partnerships, and exploring new areas like RSV sets a strong foundation for future growth.

Novavax reports $85M revenue, focuses on cost reduction and partnerships

Novavax's Q3 2024 performance showcased revenue growth and strategic cost reduction efforts.
Key strengths include a strong partnership with Sanofi and a focus on pipeline development.
Challenges ahead involve cost alignment, trial design complexities, and maintaining margins.
Opportunities lie in new pipeline programs, financial gains from partnerships, and cost optimization.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Novavax, Inc. Is a biotechnology company, which engages in the discovery, development, and commercialization of recombinant vaccines. The company was founded in 1987 and is headquartered in Gaithersburg, MD.

Currently, Novavax (NVAX) has only one marketed product in its portfolio, its protein-based COVID-19 vaccine. However, it is lagging in competition behind mRNA-based vaccines.

Novavax's (NVAX) COVID Vaccine Aids Growth, Overdependence Ails

Novavax Inc. NVAX, +2.80% said Monday that it asked the Food and Drug Administration to authorize its COVID-19 booster for adults. The company's primary series of protein-based shots received FDA authorization in July.

Novavax submits FDA application for its COVID-19 booster

If authorized, Novavax' vaccine would be the first protein-based COVID-19 booster for adults If authorized, the Novavax COVID-19 Vaccine, Adjuvanted could be used as a booster dose for adults aged 18 and older vaccinated with any other currently available COVID-19 vaccine GAITHERSBURG, Md., Aug. 15, 2022 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced that it submitted an application to the U.S. Food and Drug Administration (FDA) for Emergency Use Authorization (EUA) of its protein-based COVID-19 Vaccine, Adjuvanted for active immunization to prevent coronavirus disease 2019 (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) as a homologous and heterologous booster in adults aged 18 and older.

Novavax Submits Application to the U.S. FDA for Emergency Use Authorization for Novavax COVID-19 Vaccine, Adjuvanted as a Booster in Adults Aged 18 and Older

bluebird bio

Investing in biotech stocks without any drugs on the market can be scary. These suggestions can help you make money in this high-risk sector.

2 Tips for Investing in Biotech Stocks With High Growth Potential

Novavax, Inc. (NASDAQ: NVAX) shares are trading higher by 2.80% to $41.47, though off the session high of $43.06 after the company announced its Novaxovid COVID-19 vaccine has been approved in South Korea for use in adolescents aged 12 through 17. What Happened?

Here's Why Novavax Stock Is Trading Higher

Novavax and partner SK bioscience will provide the first protein-based COVID-19 vaccine approved for use in adolescents aged 12 through 17 years in South Korea GAITHERSBURG, Md. , Aug. 12, 2022 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced that partner, SK bioscience, has received a Post Approval Change Application approval from the Korean Ministry of Food and Drug Safety (KMFDS) for Nuvaxovid™ (NVX-CoV2373) COVID-19 vaccine for active immunization to prevent coronavirus disease 2019 (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in adolescents aged 12 through 17.

Novavax Nuvaxovid™ COVID-19 Vaccine Approved in South Korea for Use in Adolescents Aged 12 Through 17

A hugely disappointing quarter and new bear takes on the company by analysts made for a very bad set of trading days.

Why Novavax Stock Was Plummeting This Week

Believe it or not, Novavax's revenue could decline and still cause the stock to soar.

Novavax's Revenue Could Fall Even More -- and It's Actually Good News

GAITHERSBURG, Md. , Aug. 11, 2022 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced that it will participate in a fireside chat during the SVB Securities Virtual Vaccine Forum.

Novavax to Participate in Fireside Chat at the SVB Securities Virtual Vaccine Forum

Alkermes

Denali Therapeutics

S&P 500 stocks have posted average growth of 6.54% in annual total revenue from 2017 to 2021. The benchmark index for the U.S. stock market closed at 4,122.47 on Tuesday, up nearly 70% over the past five years through Aug. 9.

3 Companies Growing Revenue Fast

As a result of some bad news, the market might be underestimating its chances of a comeback.

1 Reason to Sell Novavax Stock, and 1 Reason to Buy

Novavax (NVAX) reports dismal results in second-quarter 2022. The stock dives in after-market trading after management slashes revenue guidance for 2022 by half.

Novavax (NVAX) Q2 Earnings Miss, Cuts '22 Sales Guidance by Half

Novavax fell 31% Tuesday amid falling demand for the COVID-19 shot from low and middle-income nations, which caused the company to cut its annual expectations in half.

Novavax tumbles 31% as waning COVID-19 vaccine demand hits revenue forecast

The vaccine maker reported dismal Q2 results with a bleaker outlook for the rest of the year.

Why Novavax Stock Is Plunging Today

Shares of Novavax (NASDAQ: NVAX ) stock are tanking today after the biopharmaceutical company cut its revenue guidance for this year in half. NVAX stock is down more than 30% at the time of writing.

Why Is Novavax (NVAX) Stock Plunging 30%?

Chinese authorities have closed Tibet's Potala Palace after a small outbreak of COVID cases in the Himalayan autonomous region, the Associated Press reported Tuesday.

China closes Tibet's Potala Palace over COVID outbreak, and Novavax stock is slammed by weak earnings and halving of sales guidance

The Covid-19 vaccine maker says it expects revenue this year of $2 billion to $2.3 billion, down from previous expectations of $4 billion to $5 billion.

Novavax Stock Slides on Steep Cut to Sales Forecast

U.S. vaccine maker Novavax slumped nearly 31% on Tuesday as falling demand for its COVID-19 shot from low- and middle-income nations led the company to cut its annual revenue expectation by half.

Novavax tumbles 31% as waning COVID vaccine demand hits revenue forecast

Sales of Novavax's COVID-19 vaccine won't be anywhere close to earlier projections.

Novavax Stock Is Crashing: These 3 Words Explain Why

Shares in Novavax, Inc. (NASDAQ:NVAX) tanked 33.64% in after-hours trading after the company halved its full-year revenue forecast due to a global supply glut and weak demand for its Covid-19 vaccine. Shares were trailing at US$57.25 on Nasdaq as the company missed financial expectations.

Novavax slumps after halving its sales forecast amid global supply glut and low vaccine demand

Novavax Stock Slides 29% on Steep Cut to Sales Forecast

Novavax, Inc. (NASDAQ:NVAX ) Q2 2022 Earnings Conference Call August 8, 2022 4:30 PM ET Company Participants Silvia Taylor – Senior Vice President-Global Corporate Affairs and Investor Relations Stan Erck – President and Chief Executive Officer Filip Dubovsky – Chief Medical Officer John Trizzino – Chief Commercial Officer and Chief Business Officer Jim Kelly – Chief Financial Officer and Treasurer Greg Glenn – President-Research and Development Conference Call Participants Georgi Yordanov – Cowen and Co Roger Song – Jefferies Mayank Mamtani – B. Riley Eric Joseph – JPMorgan Alec Stranahan – Bank of America Operator Good morning and welcome to Novavax Second Quarter 2022 Financial Results and Operational Highlights Conference Call.

Novavax, Inc.'s (NVAX) CEO Stan Erck on Q2 2022 Results - Earnings Call Transcript

Novavax (NVAX) delivered earnings and revenue surprises of -218.51% and 82.16%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Novavax (NVAX) Reports Q2 Loss, Misses Revenue Estimates

Investors sold out of the company after it fell short with second-quarter results.

Why Novavax Stock Got Mashed on Monday

Shares of Novavax Inc (NASDAQ: NVAX) tanked nearly 35% in extended trading on Monday after the biotech company reported thoroughly disappointing results for its fiscal second quarter and lowered its annual sales outlook by 50%. Novavax Q2 financial highlights Lost $510.5 million versus the year-ago $352 million Per-share loss climbed from $4.75 to $6.

News for Novavax Stock (NVAX)